Latest Conference Articles

Neoadjuvant therapy in early breast cancer has evolved during the past 2 decades from use primarily in large inoperable tumors to a standard treatment option for patients with early-stage HER2-positive and triple-negative breast cancer.

Age and the molecular subtype were more closely associated with long-term outcomes compared with the use of either breast-conserving surgery or mastectomy for patients with breast cancer.

Immunotherapy will be most effective as a treatment for breast cancer when it is used to alter the tumor microenvironment, according to a careful examination of studies exploring the immune response presented by Nora Disis, MD.

The paucity of patients participating in clinical trials makes data extrapolation and application complex, calling for a need to explore health technology solutions that tap the potential of real-world data.

Inhibition of CDK4/6 results in improvements in progression-free survival in women with estrogen receptor-positive/HER2-negative metastatic breast cancer whether it is endocrine sensitive or resistant.

Andrew Kennedy, MD, speaks on the various approaches used in clinical practice to treat patients who have colorectal cancer with liver metastases.

Giuseppe Curigliano, MD, PhD, discusses recent trials of immunotherapy and chemotherapy in triple-negative breast cancer, as well as the future role of immunotherapy in the treatment of breast cancer.

Daniel F. Hayes, MD, professor University of Michigan Comprehensive Cancer Center, discusses the use of tumor biomarker tests in breast cancer.

Brian Hemphill, MD, provides insight on some of the challenges currently being faced in gastrointestinal malignancies and how molecular profiles of tumors will dramatically change outcomes for these patients.

Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses the importance of de-escalating treatment in early-stage breast cancer.

Genomic studies have made significant advancements in discovering methods to combat resistance to endocrine therapy in patients with hormone receptor (HR)–positive breast cancer over the past few years, according to Ian E. Krop, MD, PhD. Of particular interest are combination therapies blocking multiple driver pathways and resistance mechanisms.

Updated findings from the MONALEESA-2 trial demonstrated that the response to ribociclib (Kisqali) in postmenopausal women with hormone-receptor-positive/HER2-negative advanced or metastatic breast cancer was unaffected by either prior endocrine treatment or prior chemotherapy.

Bert O'Neil, MD, discusses the need for novel treatments for patients with metastatic colorectal cancer as well as why researchers need to develop a deeper understanding of tumor biology.

C. Kent Osborne, MD, discusses current strategies for overcoming resistance to HER2-targeting agents in early breast cancer today.

Johanna Bendell, MD, discusses the promising impact of immunotherapy and other emerging agents in the field of gastrointestinal cancer.

Matthew Ellis, MD, PhD, director, Smith Breast Center, Baylor College of Medicine, discusses questions regarding the impact of CDK4/6 inhibitors in breast cancer.

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the death of chemotherapy and rise of targeted agents in the treatment of patients with HER2-positive breast cancer.

An immunotherapy targeting HPV-infected cells led to an unprecedented 1-year survival rate in patients with recurrent, metastatic cervical cancer.

Maintenance chemotherapy after debulking surgery and adjuvant platinum-based chemotherapy did not improve overall survival rates in women with ovarian cancer who had achieved complete remission.

Maintenance therapy with olaparib showed a 70% reduction in the risk of progression or death compared with placebo for patients with platinum-sensitive, relapsed, BRCA-mutant ovarian cancer.

Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.

Alon Altman, MD, associate professor, Department of Obstertrics, Gynecology and Reproductive Sciences, University of Manitoba, discusses neoadjuvant chemotherapy for patients with high-grade serous carcinoma.

Treatment with a carboplatin desensitization regimen led to improved overall survival in patients with BRCA-proficient ovarian cancer.

Mismatch repair-deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors.

The PARP inhibitor niraparib improved progression-free survival in patients with recurrent, platinum-sensitive, high-grade ovarian cancer, regardless of BRCA status, according to a review of the phase III ENGOT-OV16/NOVA trial presented at the 2017 Society of Gynecologic Oncology Annual Meeting.

Jubilee Brown, MD, obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer.

A survey was given to parents of teenage girls in an effort to understand the relatively low uptake of the HPV vaccine in the United States.

Hypermethylation of 2 wild-type tumor-associated genes increased ovarian cancer responsiveness to the PARP inhibitor rucaparib (Rubraca).

Lack of clinical coverage and time off topped the perceived hindrances to gynecologic oncologists’ participation in global health activities, according to a study reported at the Society of Gynecologic Oncology in National Harbor, MD.